KYMR Q4 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-61.3% YoY

Gross Profit

$79M2763.6% margin

Operating Income

-$98M-3422.9% margin

Net Income

-$87M-3043.0% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$67M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$163M

Stockholders' Equity

$1.6B

Cash & Equivalents

$357M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$7M	-61.3%
Gross Profit	$79M	$7M	+968.9%
Operating Income	-$98M	-$81M	-21.2%
Net Income	-$87M	-$71M	-23.0%